Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Taberminogene vadenovec

Drug Profile

Taberminogene vadenovec

Alternative Names: EG004; Trinam; Vascular endothelial growth factor D gene therapy - Trizell

Latest Information Update: 16 Mar 2011

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ark Therapeutics
  • Class Gene therapies; Vascular disorder therapies
  • Mechanism of Action Gene transference; Vascular endothelial growth factor D expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Vascular restenosis
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Vascular restenosis

Most Recent Events

  • 09 Sep 2010 Taberminogene vadenovec is available for licensing as of 09 Sep 2010. http://www.arktherapeutics.com
  • 14 May 2010 Phase-II/III clinical trials in Vascular restenosis in USA (IM)
  • 05 May 2010 Taberminogene vadenovec is available for licensing worldwide (http://www.arktherapeutics.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top